Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea
figure
posted on 2021-01-21, 14:29 authored by Adis journals on behalf of, So-Young Ha, Yoon-Bo Shim, Min-Young Lee, Bon-San Koo, Jae-Hoon Kim, Ja-Young Jeon, Hyun-Jeong Yoo, Young-Joo Kim, Ju-Young Shin, Mi-Hai ParkArticle full text
The above summary slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.
